Clinical Trial Update: Exploratory Study on the Safety and Efficacy of Disitamab Vedotin in Combination with Anlotinib Hydrochloride for the Treatment of HER-2-expressing Recurrent Platinum-resistant Ovarian Cancer. [EARLY_Phase 1]

View source ↗

Summary

This is an early-phase exploratory study evaluating the safety and potential efficacy of Disitamab Vedotin in combination with Anlotinib Hydrochloride for HER-2…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ovarian Cancer

Drugs mentioned

• Anlotinib hydrochloride (anlotinib)
• Disitamab Vedotin (disitamab vedotin)

Snippet

Sponsor: Second Xiangya Hospital of Central South University | Conditions: Ovarian Cancer Recurrent | EARLY_Phase 1 | Status: RECRUITING